Tracleer “Dear Doctor” Letter Emphasizes Monthly Liver Monitoring
This article was originally published in The Pink Sheet Daily
Reports of hepatotoxicity are included in boxed warning for Actelion’s pulmonary arterial hypertension therapy.
You may also be interested in...
BUILD studies fail to show effect of bosentan on primary endpoints of exercise improvement, but positive morbidity/mortality trends were seen in idiopathic pulmonary fibrosis patients.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.